On September 21, Insilico Medicine announced a tens-of-millions-of-dollars collaboration with a frontier foundation model laboratory to jointly develop, validate, and commercialize a range of cutting-edge models designed for biology research, based on the MMAI Gym training framework.
In an interview, Insilico Medicine co-CEO and chief scientific officer Ren Feng said AI drug discovery has entered its "second half," with the focus shifting from improving R&D efficiency to improving success rates. He highlighted the company's H1 2026 revenue of $106.3 million (up 287.2% year-on-year), its first half-year profit since listing, cumulative contracted value of about $11 billion, 13 IND-approved drug candidates, and Rentosertib's Phase III trial with topline data expected in 2029.
The 2026 Zhangjiang Pharma Conference and the opening forum of Shanghai International Biomedical Industry Week were held, featuring a fireside chat between Nobel Chemistry laureate Michael Levitt and Insilico Medicine CEO Ren Feng. Levitt said AI-driven drug development has surpassed his expectations, while Ren's team has advanced the world's first innovative drug with AI-identified targets and AI-designed molecular structures into Phase III clinical trials.
On September 10, Insilico Medicine announced that the first patient had been enrolled and dosed in the Phase III clinical trial of Rentosertib at Peking Union Medical College Hospital in Beijing, with the first patient also enrolled at Shanghai Pulmonary Hospital on the same day. The drug is the world's first to enter Phase III clinical trials with an AI-discovered target and an AI-designed molecule.